Should I buy or sell Kiora Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KPRX shares. View KPRX analyst ratings or view top-rated stocks .

What is Kiora Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 12 month price targets for Kiora Pharmaceuticals' shares. Their KPRX share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,150.0% from the stock's current price. View analysts price targets for KPRX or view top-rated stocks among Wall Street analysts .

How have KPRX shares performed in 2024?

Kiora Pharmaceuticals' stock was trading at $0.5224 at the beginning of 2024. Since then, KPRX stock has increased by 7.2% and is now trading at $0.56. View the best growth stocks for 2024 here .

Are investors shorting Kiora Pharmaceuticals?

Kiora Pharmaceuticals saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 49,500 shares, a decline of 42.7% from the March 15th total of 86,400 shares. Based on an average trading volume of 1,600,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.7% of the shares of the stock are short sold. View Kiora Pharmaceuticals' Short Interest .

When is Kiora Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our KPRX earnings forecast .

How were Kiora Pharmaceuticals' earnings last quarter?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) issued its earnings results on Monday, November, 15th. The company reported ($11.60) earnings per share for the quarter, beating the consensus estimate of ($13.48) by $1.88.

When did Kiora Pharmaceuticals' stock split?

Kiora Pharmaceuticals shares reverse split on Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Kiora Pharmaceuticals?

Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KPRX

Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free KPRX Stock Alerts

$0.56

-0.01 (-1.75%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.55
▼
$0.58
50-Day Range: $0.56
▼
$0.76
52-Week Range: $0.46
▼
$5.25

Volume: 44,946 shs
Average Volume: 225,066 shs
Market Capitalization: $14.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get Kiora Pharmaceuticals alerts:

Kiora Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,150.0% Upside
$7.00 Price Target
Short Interest: Healthy
0.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.01
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.05 out of 5 stars

Medical Sector

363rd out of 928 stocks

Pharmaceutical Preparations Industry

163rd out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Kiora Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.71% of the float of Kiora Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kiora Pharmaceuticals has recently decreased by 42.71%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Kiora Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Kiora Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KPRX.

2.8

News and Social Media Coverage

News Sentiment
Kiora Pharmaceuticals has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Kiora Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for KPRX on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.50% of the stock of Kiora Pharmaceuticals is held by insiders.
Percentage Held by Institutions
76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
Kiora Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Kiora Pharmaceuticals Stock (NASDAQ:KPRX)

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

KPRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KPRX Stock News Headlines

March 25, 2024 | msn.com

Kiora Pharmaceuticals reports FY results

February 9, 2024 | markets.businessinsider.com

Kiora Pharmaceuticals: Strong Buy Rating on Strategic Partnership and Promising Trial Results

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

February 9, 2024 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To Know

February 1, 2024 | msn.com

What's Going On With Kiora Pharmaceuticals Stock?

February 1, 2024 | benzinga.com

Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

February 1, 2024 | msn.com

Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today?

January 31, 2024 | msn.com

Kiora stock soars after hours on deal with Thea Open Innovation

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

January 31, 2024 | finance.yahoo.com

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties

January 31, 2024 | finance.yahoo.com

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

January 9, 2024 | morningstar.com

Kiora Pharmaceuticals Inc KPRX

November 17, 2023 | finance.yahoo.com

Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301

November 11, 2023 | benzinga.com

Kiora Pharmaceuticals Stock (NASDAQ:KPRX) Earnings Dates and Earning Calls

November 9, 2023 | msn.com

Kiora Pharmaceuticals reports Q3 results

November 9, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

November 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Kiora Pharmaceuticals (KPRX) and Bluebird Bio (BLUE)

November 6, 2023 | markets.businessinsider.com

Analyst Expectations for Kiora Pharmaceuticals's Future

November 4, 2023 | finance.yahoo.com

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

October 16, 2023 | finance.yahoo.com

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

October 3, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

September 21, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

September 18, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

September 14, 2023 | finance.yahoo.com

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

September 1, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

August 29, 2023 | finance.yahoo.com

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

August 24, 2023 | finance.yahoo.com

Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis

See More Headlines

Receive KPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KPRX
CUSIP: N/A
CIK: 1372514
Web: eyegatepharma.com
Phone: (781) 788-9043
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +1,150.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,510,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -131.68%
Return on Assets: -75.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.90
Quick Ratio: 2.90

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.79 per share
Price / Book: 0.71

Miscellaneous

Outstanding Shares: 26,260,000
Free Float: 25,862,000
Market Cap: $14.71 million
Optionable: Not Optionable
Beta: -0.26

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Brian M. Strem Ph.D. (Age 44)
President, CEO & Director
Comp: $464.93k
Dr. Eric J. Daniels M.B.A. (Age 50)
M.D., Chief Development Officer
Comp: $371.47k
Dr. Stefan Sperl Ph.D.
Executive Vice President of CMC & Operations

Key Competitors

View All Competitors

Institutional Ownership

Citadel Advisors LLC
Bought 92,585 shares on 2/15/2024
Ownership: 1.204%

View All Institutional Transactions

KPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiora Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KPRX shares.
View KPRX analyst ratings or view top-rated stocks.
What is Kiora Pharmaceuticals' stock price target for 2024?: 1 equities research analysts have issued 12 month price targets for Kiora Pharmaceuticals' shares. Their KPRX share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,150.0% from the stock's current price.
View analysts price targets for KPRX or view top-rated stocks among Wall Street analysts.
How have KPRX shares performed in 2024?: Kiora Pharmaceuticals' stock was trading at $0.5224 at the beginning of 2024. Since then, KPRX stock has increased by 7.2% and is now trading at $0.56.
View the best growth stocks for 2024 here.
Are investors shorting Kiora Pharmaceuticals?: Kiora Pharmaceuticals saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 49,500 shares, a decline of 42.7% from the March 15th total of 86,400 shares. Based on an average trading volume of 1,600,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.7% of the shares of the stock are short sold.
View Kiora Pharmaceuticals' Short Interest.

When is Kiora Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our KPRX earnings forecast.
How were Kiora Pharmaceuticals' earnings last quarter?: Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) issued its earnings results on Monday, November, 15th. The company reported ($11.60) earnings per share for the quarter, beating the consensus estimate of ($13.48) by $1.88.
When did Kiora Pharmaceuticals' stock split?: Kiora Pharmaceuticals shares reverse split on Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
How do I buy shares of Kiora Pharmaceuticals?: Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KPRX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial